Literature DB >> 2193078

Cytoplasmic components of natural killer cells limit the growth of Cryptococcus neoformans.

M R Hidore1, N Nabavi, C W Reynolds, P A Henkart, J W Murphy.   

Abstract

Murine natural killer (NK) cell-mediated inhibition of growth of a yeast-like target cell, Cryptococcus neoformans, was completely abrogated by blocking the effector cell secretory process with monensin. Therefore, further studies were performed to determine the ability of various cytoplasmic fractions of NK cells to mediate inhibition of cryptococcal growth. Percoll-fractionated homogenates of rat LGL tumor cells demonstrated that the granule-containing fractions plus three additional sets of less dense cytoplasmic fractions displayed anti-cryptococcal activity; whereas only the cytoplasmic granule-containing fractions had cytotoxic activity against YAC-1 tumor cell and sheep erythrocyte targets. Maximal cryptococcal growth inhibition induced by LGL granules occurred after a 1 h incubation, required the presence of Ca2+ (1.0 mM) or Mg2+ (0.5 mM or 5.0 mM), and was completely abrogated in the presence of rabbit anti-LGL granule IgG. Cytolysin, the granule component which mediates tumor cell and sheep erythrocyte lysis, effectively limited the growth of cryptococci. Since Percoll gradient fractionation of the LGL homogenates demonstrated three separate peaks of anti-cryptococcal activity other than the granule peak, it is possible that the cytolysin-containing granules are not the only subcellular component of NK cells playing a role in inhibition of C. neoformans growth.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2193078     DOI: 10.1002/jlb.48.1.15

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  13 in total

1.  The Cnes2 locus on mouse chromosome 17 regulates host defense against cryptococcal infection through pleiotropic effects on host immunity.

Authors:  Mitra Shourian; Adam Flaczyk; Isabelle Angers; Barbara C Mindt; Jörg H Fritz; Salman T Qureshi
Journal:  Infect Immun       Date:  2015-09-14       Impact factor: 3.441

2.  Binding interactions of murine natural killer cells with the fungal target Cryptococcus neoformans.

Authors:  J W Murphy; M R Hidore; N Nabavi
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

3.  Responses of murine natural killer cells to binding of the fungal target Cryptococcus neoformans.

Authors:  M R Hidore; T W Mislan; J W Murphy
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

4.  Direct interactions of human natural killer cells with Cryptococcus neoformans inhibit granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha production.

Authors:  J W Murphy; A Zhou; S C Wong
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

5.  Murine natural killer cells are fungicidal to Cryptococcus neoformans.

Authors:  M R Hidore; N Nabavi; F Sonleitner; J W Murphy
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

6.  Growth inhibition of Candida albicans by interleukin-2-activated splenocytes.

Authors:  D W Beno; H L Mathews
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

7.  Direct interactions of human lymphocytes with the yeast-like organism, Cryptococcus neoformans.

Authors:  J W Murphy; M R Hidore; S C Wong
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

8.  Direct anticryptococcal activity of lymphocytes from Cryptococcus neoformans-immunized mice.

Authors:  S M Muth; J W Murphy
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

9.  Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans.

Authors:  S M Levitz; M P Dupont; E H Smail
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

Review 10.  Natural killer cells and antifungal host response.

Authors:  Stanislaw Schmidt; Stefanie-Yvonne Zimmermann; Lars Tramsen; Ulrike Koehl; Thomas Lehrnbecher
Journal:  Clin Vaccine Immunol       Date:  2013-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.